Abstract
MoST-LLy (Molecular Screening and Therapeutics in Leukaemia and Lymphoma) has a unique study design with molecular screening using Illumina’s TruSight™ Oncology 500 Next Generation Sequencing (NGS) assay, and linking patients with advanced haematological malignancy with no standard of care treatment, to access targeted clinical trials and treatments they would otherwise not have access to.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
